A Single Dose, 2-Period, Cross-Over, Bioequivalence Study in Healthy Subjects to Evaluate the Proposed Commercial Oral Suspension of Candesartan Cilexetil.
Phase of Trial: Phase I
Latest Information Update: 06 Dec 2010
At a glance
- Drugs Candesartan cilexetil (Primary)
- Indications Hypertension
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 06 Dec 2010 Actual initiation date changed from Mar 2008 to Mar 2009 as reported by ClinicalTrials.gov.
- 19 Jun 2009 Actual initiation date (Mar 2008), actual patient number (36) added as reported by ClinicalTrials.gov.
- 19 Jun 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.